# Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Children, Adolescents and Adults in Russia

> **NCT01725217** · PHASE3 · COMPLETED · sponsor: **Novartis Vaccines** · enrollment: 198 (actual)

## Conditions studied

- Meningococcal Disease

## Interventions

- **BIOLOGICAL:** MenACWY-CRM

## Key facts

- **NCT ID:** NCT01725217
- **Lead sponsor:** Novartis Vaccines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 198 (ACTUAL)
- **Last updated:** 2023-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01725217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01725217, "Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Children, Adolescents and Adults in Russia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01725217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*